Original Article
Clinicopathologic correlation of endometrial stromal sarcomas: a retrospective study of 42 cases
Abstract
Background: To evaluate clinicopathologic features and molecular markers associated with prognosis and diagnosis of endometrial stromal sarcomas (ESS) and analyze prognostic values.
Methods: We analyzed the clinic and pathologic records of 42 patients who were diagnosed with ESS from the First Affiliated Hospital of Chongqing Medical University between January 2012 and August 2017 retrospectively, and further explored the correlation between pathological features and prognosis.
Results: The age of the patients ranged from 20 to 74 years (mean: 45.5 years). There were 24 low-grade ESS (LGESS), 16 high-grade ESS (HGESS) and 2 undifferentiated uterine sarcoma (UUS) respectively, of which included 6 recurrent cases involving extra-uterine organs. The tumors of most patients usually showed positive for CD10, Vimentin, ER, PR, CyclinD1, and negative for SMA and S-100 with immunohistochemical staining. Tumor classification, depth of invasion, and tumor stage showed correlation with the recurrence rate (P<0.01, 0.05, and 0.01). CyclinD1 expression was significantly associated with tumor recurrence (P<0.01), and ER, PR with tumor classification (P<0.05, 0.01).
Conclusions: Our results demonstrate that CyclinD1 positivity may contribute to tumor recurrence and malignancy associated with ESS. Tumor classification, depth of invasion, and tumor stage show significant association with the recurrences.
Methods: We analyzed the clinic and pathologic records of 42 patients who were diagnosed with ESS from the First Affiliated Hospital of Chongqing Medical University between January 2012 and August 2017 retrospectively, and further explored the correlation between pathological features and prognosis.
Results: The age of the patients ranged from 20 to 74 years (mean: 45.5 years). There were 24 low-grade ESS (LGESS), 16 high-grade ESS (HGESS) and 2 undifferentiated uterine sarcoma (UUS) respectively, of which included 6 recurrent cases involving extra-uterine organs. The tumors of most patients usually showed positive for CD10, Vimentin, ER, PR, CyclinD1, and negative for SMA and S-100 with immunohistochemical staining. Tumor classification, depth of invasion, and tumor stage showed correlation with the recurrence rate (P<0.01, 0.05, and 0.01). CyclinD1 expression was significantly associated with tumor recurrence (P<0.01), and ER, PR with tumor classification (P<0.05, 0.01).
Conclusions: Our results demonstrate that CyclinD1 positivity may contribute to tumor recurrence and malignancy associated with ESS. Tumor classification, depth of invasion, and tumor stage show significant association with the recurrences.
